ETH-615 is an amphoteric drug that forms a water-insoluble zwitterion at intermediate pH values. Increasing the aqueous solubility of ETH-615 through cyclodextrin complexation did not enhance transdermal delivery of the drug from saturated aqueous solutions. However, increasing the lipophilicity of the drug through masking of the anionic group with a pro-moiety increased the dermal and transdermal delivery of the drug. Furthermore, masking the anionic group enhanced the chemical stability of the drug, resulting in significant improvement of the shelf life of the drug in both aqueous and nonaqueous solutions.

01 Jan 2000·Skin Pharmacology and Physiology

Preview of Potential Therapeutic Applications of Leukotriene B4 Inhibitors in Dermatology

Review

Author: Zhu, Y. Isabel ; Stiller, Matthew J.

This article reviews the mechanisms and potential therapeutic uses of compounds with inhibitory effects on leukotriene B4 (LTB4) production or its activity, and focuses on compounds that have been shown in animal and/or human studies to have potential efficacy in treating dermatological disorders. These compounds, many of which are not familiar to many dermatologists, include inhibitors of 5-lipoxygenase such as ETH615, 15-hydroxyeicosatetraenoic acid, leflunomide, linetastine, lonapalene, MK886, R-68151 and zileuton, and antagonists of LTB4 such as SC53228, SC50605, SC51146 and VML295. The purpose of this paper is to introduce our colleagues to these potentially useful compounds currently in preclinical or early clinical testing.

01 May 1998·Journal of Experimental BiologyQ2 · BIOLOGY

Cell Volume Regulation In Proximal Renal Tubules From Trout (Salmo Trutta)

Q2 · BIOLOGY

Article

Author: Norderhus, Eli ; Kanli, Hilde

ABSTRACTRegulatory volume decrease (RVD) following hypo-osmotic stimulation was studied using videometric methods in isolated proximal renal tubules from trout (Salmo trutta). The relative tubule diameter increased by 132.0±4.8 % (maximum swelling within 1 min at 15 and 25 °C and within 4 min at 10 °C) following a change from iso-osmotic (290 mosmol kg−1) to hypo-osmotic (160 mosmol kg−1) Ringer’s solution. The tubule diameter subsequently decreased to approximately one-quarter of the maximal value. Ouabain (1 mmol l−1) reduced cell swelling and inhibited the RVD response by 28.0±10.5 %. Furthermore, increasing the bath K+ concentration by 30 mmol l−1 inhibited RVD by 76.5±3.6 %. The K+ channel blocker quinine, but not Ba2+ (1 and 2 mmol l−1), significantly decreased the RVD response (by 25.0±5.4 and 72.3±5.1 % at 0.1 and 0.5 mmol l−1, respectively). Similarly, increasing the Cl− concentration in the bath from 47 to 102 mmol l−1 induced a significant reduction (45.2±7.9 %) in RVD. The RVD response was also markedly reduced (by 54.7±5.3 %) by the Cl− channel blocker indacrinone (MK-196; 0.5 mmol l−1), but only marginally by 5-nitro-2-(3-phenylpropylamino)benzoic acid (NPPB; 1, 5, 8 and 10 µmol l−1). Addition of the K+/Cl− symport inhibitor furosemide (0.1 mmol l−1) resulted in a 39.8±3.9 % inhibition of RVD. This inhibition could be completely overcome by simultaneous administration of 1 µmol l−1 tributyltin (anion exchanger) and furosemide.Chelation of either extracellular (1 mmol l−1 EGTA) or both extra- and intracellular Ca2+ (1 mmol l−1 EGTA, 10 µmol l−1 A23187) had no effect on this RVD process. Furthermore, as measured using the fluorescent dye Fura-2/AM, there was no increase in the intracellular free Ca2+ concentration upon hypo-osmotic stimulation. Administration of the 5-lipoxygenase antagonist ETH 615-139 (20 µmol l−1), however, induced a 60 % inhibition of RVD. Simultaneous addition of ETH-615 and either the K+ ionophore gramicidin (0.5 mmol l−1) or the anion exchanger tributyltin (1 µmol l−1) could not reverse the ETH 615-139 inhibition. Finally, administration of the cycloxygenase inhibitor indomethacin had only a small, but significant, effect on RVD.We conclude that RVD following hypo-osmotic swelling is in these cells a temperature- and ouabain-sensitive process that appears to be the result of K+ efflux through quinine-sensitive, Ba2+-insensitive K+ channels and Cl− efflux through an MK-196- and furosemide-sensitive Cl− conductance that is relatively unaffected by NPPB. This KCl efflux seems to be regulated by eicosanoids produced by the 5-lipoxygenase. Arachidonic acid metabolites from the cycloxygenase pathway are not involved in this process. Similarly, neither extra-nor intracellular Ca2+ appears to be important for the signalling of RVD.

100 Deals associated with ETH-615

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dermatitis	Phase 2	EU	-	-
Dermatitis	Phase 2	-	Leo Pharma, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

ETH-615

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation